ABPath Blood Banking/Transfusion Medicine common mistakes
ABPath Blood Banking/Transfusion Medicine · Understand the traps and how to avoid them.
Treating donor deferral as a single permanent decision instead of distinguishing permanent from temporary deferrals and the specific re-entry/reinstatement pathway for each reason (e.g., deferral for malaria exposure vs. a permanent deferral for a prior reactive hepatitis test).
Candidates memorize lists of deferral reasons but not the duration or the re-entry mechanism, so they answer the 'when can this donor return' question with the wrong interval or assume a permanent bar.
What to do instead
Build a two-column table for every deferral reason: duration (temporary/permanent) and re-entry pathway (time-based, negative test, physician re-entry, not eligible). Practice scenario questions asking 'earliest date this donor may donate' and 'what must occur before re-entry.'
Applying a single storage temperature and expiration to all red cell products, ignoring that the shelf life and storage conditions change with the additive solution, the anticoagulant, and whether the unit was opened or pooled.
The candidate recalls 'red cells are 42 days at 1-6 C' as a universal fact and does not check whether the question specifies AS-1/AS-3, CPDA-1, an open system, or an irradiated or washed unit.
What to do instead
Memorize the storage/expiration matrix by product and condition: additive-solution RBCs vs. CPDA-1, open-system expiration (24 hours at 1-6 C), post-irradiation expiration, post-wash expiration, and deglycerolized RBC expiration. For each question, identify the exact product and modification before selecting a date.
Choosing a blood product for a patient with a known antibody based on the patient's ABO type alone, without confirming that the selected unit is antigen-negative for the corresponding clinically significant antibody and crossmatch-compatible.
Candidates focus on ABO compatibility and forget that the antibody identification result must drive antigen-negative unit selection; they also may not recognize which antibodies are clinically significant enough to require antigen-negative units.
What to do instead
Use a two-step algorithm for every product-selection question: (1) ABO/Rh compatibility, (2) antigen-negative requirement for clinically significant antibodies (e.g., anti-K, anti-Jka, anti-D, anti-S). Practice by listing, for each common antibody, the antigen-negative unit needed and whether AHG crossmatch is required.
Misinterpreting a positive antibody screen or crossmatch as a single antibody and stopping identification before excluding underlying alloantibodies or autoantibodies (e.g., reporting anti-D when the pattern also fits anti-C plus anti-e, or missing a warm autoantibody).
Candidates stop at the first antibody that fits the panel rather than systematically ruling out cells and checking for dosage, phase, and reaction strength consistent with additional antibodies.
What to do instead
Apply a structured method: rule out using homozygous and heterozygous cells, check phase of reactivity, perform selected-cell panels and enzyme/chemical treatment when indicated, and always ask 'could a second antibody or an autoantibody explain the remaining reactions?' Practice with multi-antibody and autoantibody cases.
Transfusing platelets or plasma for a numeric threshold alone without assessing the clinical context (active bleeding, planned procedure, evidence of platelet dysfunction, or volume status), or delaying transfusion in an actively bleeding patient to wait for a lab value.
Candidates treat restrictive transfusion thresholds as absolute rules rather than context-dependent triggers, and they conflate prophylactic with therapeutic indications.
What to do instead
For each component, memorize both the prophylactic threshold and the therapeutic indication (e.g., platelets for bleeding with dysfunction regardless of count; plasma for bleeding with coagulopathy, not for a prolonged INR alone). Practice questions that present a bleeding patient with a near-normal count and ask what to do next.
Attributing a transfusion reaction to a single cause without working through the differential by timing and presenting signs (e.g., calling fever a febrile nonhemolytic reaction when the patient also has hypotension, or missing delayed hemolytic anemia presenting days later).
Candidates anchor on the most common reaction and do not systematically consider hemolytic (acute vs. delayed), septic, allergic/anaphylactic, TRALI, TACO, and hypotensive reactions by their timing and distinguishing features.
What to do instead
Create a timing-and-signs grid: onset (immediate, minutes-hours, days), fever, hypotension, respiratory findings, hemoglobin/ bilirubin changes, and the first action for each. Practice distinguishing TRALI from TACO (fluid status, BNP, response to diuresis) and acute from delayed hemolytic reactions.
Confusing patient blood management strategies with simple transfusion restriction, and failing to recognize preoperative anemia optimization, cell salvage, antifibrinolytics, and normovolemic hemodilution as PBM interventions.
Candidates equate PBM with 'transfuse less' and do not connect the three-pillar framework (optimize erythropoiesis, minimize blood loss, harness tolerance of anemia) to specific clinical actions.
What to do instead
Memorize the three PBM pillars and one or two concrete interventions per pillar. Practice questions that ask which preoperative or intraoperative intervention best reduces allogeneic exposure in a given surgical scenario.
Conflating donor apheresis eligibility with therapeutic apheresis indications, or applying whole-blood donation criteria unchanged to apheresis donors (e.g., interval between plateletpheresis procedures, total plasma volume limits, or concurrent donation rules).
Candidates learn one set of donation criteria and apply it to all apheresis procedures without accounting for procedure-specific intervals, volume limits, and the distinction between donor and patient (therapeutic) procedures.
What to do instead
Build a separate table for apheresis donor criteria: minimum intervals by procedure type, annual plasma/platelet volume limits, and which tests are required. Separately memorize therapeutic apheresis indications by ASFA category and the urgency of each.
Treating HLA matching as a single 'match/mismatch' determination without distinguishing HLA class I vs. class II, antibody-mediated vs. cellular rejection, and the difference between donor selection for solid organ transplant vs. hematopoietic cell transplant.
Candidates memorize HLA nomenclature but do not connect it to the clinical decision (which loci matter for which transplant, when crossmatching is required, and how donor-specific antibodies affect selection).
What to do instead
Map HLA class I (A, B, C) and class II (DR, DQ, DP) to their roles, then learn the donor-selection rules for kidney vs. HCT (e.g., high-resolution typing and matching requirements). Practice interpreting donor-specific antibody and crossmatch results in context.
Citing a regulatory or accreditation requirement (AABB, CAP, FACT, FDA, CGMP) without identifying which body actually governs the specific activity, or assuming one standard satisfies all.
Candidates memorize standards in isolation and do not build a map of which organization regulates donor collection, laboratory testing, cellular therapy manufacturing, or tissue banking, so they cite the wrong authority.
What to do instead
Create a jurisdiction matrix: activity (donor collection, testing, cellular therapy, tissue banking, labeling) vs. governing body (FDA CFR, AABB, CAP, FACT) and the type of requirement (regulation vs. accreditation standard). Practice questions that ask 'which standard requires...' and verify the governing body before answering.